Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) EBITDA Margin (2019 - 2023)

Historic EBITDA Margin for Benitec Biopharma (BNTC) over the last 5 years, with Q2 2023 value amounting to 66257.14%.

  • Benitec Biopharma's EBITDA Margin changed N/A to 66257.14% in Q2 2023 from the same period last year, while for Mar 2024 it was 309628.57%, marking a year-over-year decrease of 2812241600.0%. This contributed to the annual value of 25529.33% for FY2023, which is 8745400.0% down from last year.
  • As of Q2 2023, Benitec Biopharma's EBITDA Margin stood at 66257.14%.
  • Benitec Biopharma's 5-year EBITDA Margin high stood at 6157.14% for Q2 2020, and its period low was 393300.0% during Q1 2021.
  • For the 5-year period, Benitec Biopharma's EBITDA Margin averaged around 80603.12%, with its median value being 10725.0% (2020).
  • In the last 5 years, Benitec Biopharma's EBITDA Margin crashed by 2000000000bps in 2021 and then soared by 2000000000bps in 2022.
  • Benitec Biopharma's EBITDA Margin (Quarter) stood at 2277.92% in 2019, then crashed by -13263bps to 304400.0% in 2020, then skyrocketed by 94bps to 19512.0% in 2021, then crashed by -104bps to 39792.86% in 2022, then crashed by -67bps to 66257.14% in 2023.
  • Its EBITDA Margin was 66257.14% in Q2 2023, compared to 8059.26% in Q1 2023 and 39792.86% in Q4 2022.